|
Synonyms: CL-2C | NVP-QGE031 | QGE031
Compound class:
Antibody
Comment: Ligelizumab is a humanized, investigational high-affinity anti-IgE monoclonal antibody with anti-inflammatory potential [1], with improved pharmacokinetics and clinical effects compared to omalizumab.
Peptide sequences for this antibody are available from its IMGT/mAb-DB record. BLAST peptide sequence analysis reveals identical matches with antibody sequences claimed in patent US7531169 B2, where it is the clone designated as CL-2C [3]. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| References |
|
1. Arm JP, Bottoli I, Skerjanec A, Floch D, Groenewegen A, Maahs S, Owen CE, Jones I, Lowe PJ. (2014)
Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin Exp Allergy, 44 (11): 1371-85. [PMID:25200415] |
|
2. Maurer M, Weller K, Bindslev-Jensen C, Giménez-Arnau A, Bousquet PJ, Bousquet J, Canonica GW, Church MK, Godse KV, Grattan CE et al.. (2011)
Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report. Allergy, 66 (3): 317-30. [PMID:21083565] |
|
3. Singh S, Foster C, Wu H. (2009)
High affinity anti-human IgE antibodies. Patent number: US7531169 B2. Assignee: Tanox, Inc.. Priority date: 01/02/2003. Publication date: 12/05/2009. |
|
4. Trischler J, Bottoli I, Janocha R, Heusser C, Jaumont X, Lowe P, Gautier A, Pethe A, Woessner R, Zerwes HG et al.. (2021)
Ligelizumab treatment for severe asthma: learnings from the clinical development programme. Clin Transl Immunology, 10 (3): e1255. [PMID:33747510] |
